Haemonetics Corporation (FRA:HAZ)
51.00
0.00 (0.00%)
Last updated: Feb 20, 2026, 8:01 AM CET
Haemonetics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 27, 2025 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 | Apr '21 Apr 3, 2021 |
Revenue | 1,318 | 1,361 | 1,309 | 1,169 | 993.2 | 870.46 |
Revenue Growth (YoY) | -4.02% | 3.96% | 12.01% | 17.67% | 14.10% | -11.94% |
Cost of Revenue | 524.5 | 582.28 | 597.14 | 545.79 | 462.43 | 442.02 |
Gross Profit | 793.78 | 778.55 | 711.92 | 622.87 | 530.77 | 428.45 |
Selling, General & Admin | 428.89 | 422.05 | 420.82 | 373.95 | 332.2 | 263.83 |
Research & Development | 61.09 | 61.13 | 52.23 | 49.08 | 45.98 | 31.69 |
Amortization of Goodwill & Intangibles | 44.8 | 48.26 | 32.03 | 32.64 | 47.41 | 32.83 |
Operating Expenses | 534.78 | 531.45 | 505.08 | 455.67 | 425.6 | 328.35 |
Operating Income | 259 | 247.1 | 206.84 | 167.2 | 105.17 | 100.1 |
Interest Expense | -48.7 | -35.9 | -19.5 | -13 | -5.8 | -9.4 |
Currency Exchange Gain (Loss) | -7.43 | -1.53 | - | - | - | - |
Other Non Operating Income (Expenses) | 32.21 | 15.09 | 6.48 | -1.63 | -11.32 | -4.43 |
EBT Excluding Unusual Items | 235.07 | 224.75 | 193.82 | 152.57 | 88.05 | 86.26 |
Merger & Restructuring Charges | -21.63 | -45.91 | -33.54 | -11.55 | -28.82 | -25.26 |
Gain (Loss) on Sale of Assets | - | - | 2 | 0.38 | 9.6 | 32.81 |
Asset Writedown | -9.3 | -2.39 | -10.42 | - | -5.2 | -20.9 |
Other Unusual Items | 23.02 | 35.62 | - | - | - | - |
Pretax Income | 227.17 | 212.07 | 151.87 | 141.4 | 63.63 | 72.91 |
Income Tax Expense | 51.73 | 44.39 | 34.31 | 26 | 20.25 | -6.56 |
Net Income | 175.44 | 167.68 | 117.56 | 115.4 | 43.38 | 79.47 |
Net Income to Common | 175.44 | 167.68 | 117.56 | 115.4 | 43.38 | 79.47 |
Net Income Growth | 34.88% | 42.63% | 1.87% | 166.05% | -45.42% | 3.85% |
Shares Outstanding (Basic) | 48 | 50 | 51 | 51 | 51 | 51 |
Shares Outstanding (Diluted) | 48 | 51 | 51 | 51 | 51 | 51 |
Shares Change (YoY) | -6.04% | -1.30% | -0.04% | 0.13% | 0.12% | -1.01% |
EPS (Basic) | 3.66 | 3.33 | 2.32 | 2.27 | 0.85 | 1.57 |
EPS (Diluted) | 3.65 | 3.31 | 2.29 | 2.24 | 0.84 | 1.55 |
EPS Growth | 43.84% | 44.54% | 2.23% | 166.67% | -45.81% | 4.73% |
Free Cash Flow | 308.08 | 142.45 | 143.63 | 81.73 | 75.75 | 71.77 |
Free Cash Flow Per Share | 6.40 | 2.81 | 2.79 | 1.59 | 1.48 | 1.40 |
Gross Margin | 60.21% | 57.21% | 54.38% | 53.30% | 53.44% | 49.22% |
Operating Margin | 19.65% | 18.16% | 15.80% | 14.31% | 10.59% | 11.50% |
Profit Margin | 13.31% | 12.32% | 8.98% | 9.88% | 4.37% | 9.13% |
Free Cash Flow Margin | 23.37% | 10.47% | 10.97% | 6.99% | 7.63% | 8.24% |
EBITDA | 364.9 | 355.99 | 295.45 | 252.01 | 191.72 | 184.38 |
EBITDA Margin | 27.68% | 26.16% | 22.57% | 21.56% | 19.30% | 21.18% |
D&A For EBITDA | 105.91 | 108.89 | 88.62 | 84.81 | 86.55 | 84.29 |
EBIT | 259 | 247.1 | 206.84 | 167.2 | 105.17 | 100.1 |
EBIT Margin | 19.65% | 18.16% | 15.80% | 14.31% | 10.59% | 11.50% |
Effective Tax Rate | 22.77% | 20.93% | 22.59% | 18.39% | 31.83% | - |
Advertising Expenses | - | 7.7 | 7.1 | 7.2 | 4.4 | 2.7 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.